In the Driver’s Seat with Multiple Sclerosis: Optimizing DMT Selection
Optimizing DMT Selection in MS
Click the"View Activity" button to view this activity.View Activity
CME/CE is no longer available for this activity
-Interpret the latest evidence and integrate it into clinical practice
-Introduce strategies to identify patients who will benefit from specific therapies
-Apply evidence-based strategies for DMT selection and monitoring treatment response to optimize personalized management in patients with MS.
Weill Institute for Neurosciences
University of California San Francisco
San Francisco, CA
For questions, contact Ty Jackson at firstname.lastname@example.org.
This activity is being presented without bias and with commercial support.
Rush University Medical center designates this enduring material activity for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Rush University Medical Center designates this enduring material for a maximum of 1.25 contact hours.
MIPS Improvement Activity
Completion of this activity, including the pretest, posttest, and follow-up assessments, qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.